Ann: Preliminary Final Report, page-31

good point. my hypothesis is that the 2 deals they have signed, if you look at those 2 companies they are basically generics houses /distributors, they have no innovation of their own. nothing wrong with that, but maybe the kind that have lower expectations about the science, less skin in the game so let Dimx do all the development work, probably happy to dump this and move on to the next good thing if this asset takes too long to get to market as it's just another generic to them. Then you have the real kidney Pharma players, innovators, just look at what Novartis has been doing with its acquisitions for its nephrology pipeline, for some reason those players haven't touched this asset despite the same data being available to them and all the alleged "ongoing negotiations".